Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer

References

• Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43–46.
   PubMedGoogle Scholar
• Cancer today; 2018. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/breast-new.asp. Accessed 111, 2018.
   Google Scholar
• Abdel-Razeq H, Attiga F, Mansour A. Cancer care in Jordan. Hematol Oncol Stem Cell Ther. 2015;8(2):64–70. doi:10.1016/j.hemonc.2015.02.00125732671
   PubMedGoogle Scholar
• Tichy JR, Lim E, Anders CK. Breast cancer in adolescents and young adults: a review with a focus on biology. J Natl Compr Canc Netw. 2013;11(9):1060–1069.24029122
   PubMed Web of Science ®Google Scholar
• Gewefel H, Salhia B. Breast cancer in adolescent and young adult women. Clin Breast Cancer. 2014;14(6):390–395. doi:10.1016/j.clbc.2014.06.00225034440
   PubMed Web of Science ®Google Scholar
• Moore HCF. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. Curr Oncol Rep. 2000;2:587–593. doi:10.1007/s11912-000-0114-911122897
   PubMedGoogle Scholar
• Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718–1729. doi:10.1200/JCO.1996.14.5.17188622093
   PubMed Web of Science ®Google Scholar
• Anderson C, Engel SM, Anders CK, Nichols HB. Live birth outcomes after adolescent and young adult breast cancer. Int J Cancer. 2018;142(10):1994–2002. doi:10.1002/ijc.3122729266267
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999;17(8):2365–2370. doi:10.1200/JCO.1999.17.8.236510561298
   PubMed Web of Science ®Google Scholar
• Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575–1579. doi:10.1002/cncr.2138516134178
   PubMed Web of Science ®Google Scholar
• Takai Y. Recent advances in oncofertility care worldwide and in Japan. Reprod Med Biol. 2018;17(4):356–368. doi:10.1002/rmb2.1221430377391
   PubMed Web of Science ®Google Scholar
• Kelvin JF, Thom B, Benedict C, et al. Cancer and fertility program improves patient satisfaction with information received. J Clin Oncol. 2016;34(15):1780–1786. doi:10.1200/JCO.2015.64.516827044937
   PubMed Web of Science ®Google Scholar
• Oktay K, Harvey BE, Partridge A, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. doi:10.1200/JCO.2018.78.191429620997
   PubMed Web of Science ®Google Scholar
• McCray DK, Simpson AB, Flyckt R, et al. Fertility in women of reproductive age after breast cancer treatment: practice patterns and outcomes. Ann Surg Oncol. 2016;23(10):3175–3181. doi:10.1245/s10434-016-5308-y27334218
   PubMed Web of Science ®Google Scholar
• Benedict C, Thom B, N Friedman D, et al. Young adult female cancer survivors’ unmet information needs and reproductive concerns contribute to decisional conflict regarding post treatment fertility preservation. Cancer. 2016;122:2101–2109. doi:10.1002/cncr.2991727213483
   PubMed Web of Science ®Google Scholar
• Schally AV, Coy DH, Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet. 1980;18(5):318. doi:10.1002/j.1879-3479.1980.tb00507.x6110575
   PubMedGoogle Scholar
• Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324(2):93. doi:10.1056/NEJM1991011032402051984190
   PubMed Web of Science ®Google Scholar
• Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259(14):2123–2125.3162285
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod. 1995;52:365–372. doi:10.1095/biolreprod52.2.3657711205
   PubMed Web of Science ®Google Scholar
• Lobo RA. Potential options for preservation of fertility in women. N Engl J Med. 2005;353:64–73. doi:10.1056/NEJMra04347516000356
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044–1054. doi:10.1634/theoncologist.12-9-104417914074
   PubMed Web of Science ®Google Scholar
• Kitajima Y, Endo T, Nagasawa K, et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006;147:694–699. doi:10.1210/en.2005-070016269461
   PubMed Web of Science ®Google Scholar
• Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009;117:561–567. doi:10.1007/s10549-009-0313-519153828
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009;91:694–697. doi:10.1016/j.fertnstert.2007.12.04418675959
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269–276. doi:10.1001/jama.2011.99121771987
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al.; for the GIM Study Group. Ovarian suppression with Triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a Randomized Clinical Trial. JAMA. 2015;314:2632–2640. doi:10.1001/jama.2015.1729126720025
   PubMed Web of Science ®Google Scholar
• Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30:667. doi:10.1007/s12032-013-0667-823904400
   PubMed Web of Science ®Google Scholar
• Leonard RCF, Adamson DJA, Bertelli G, et al; Anglo Celtic Collaborative Oncology Group and National Cancer Research Institute Trialists. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol. 2017;28:1811–1816.28472240
   PubMed Web of Science ®Google Scholar
• Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30:533–538. doi:10.1200/JCO.2011.34.689022231041
   PubMed Web of Science ®Google Scholar
• Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013;121:78–86. doi:10.1097/AOG.0b013e31827374e223262931
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al.; POEMS/S0230 Investigators. Goserelin for ovarian protection on during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–932. doi:10.1056/NEJMoa141320425738668
   PubMed Web of Science ®Google Scholar
• Gerber B, von Minckwitz G, Stehle H, et al.; German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function on after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29:2334–2341. doi:10.1200/JCO.2010.32.570421537042
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40:675–683. doi:10.1016/j.ctrv.2013.12.00124360817
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies. Ann Oncol. 2015;26:2408–2419. doi:10.1093/annonc/mdv37426347105
   PubMed Web of Science ®Google Scholar
• Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:65–73. doi:10.1001/jamaoncol.2015.325126426573
   PubMed Web of Science ®Google Scholar
• Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015;126:187–195. doi:10.1097/AOG.000000000000090526241272
   PubMed Web of Science ®Google Scholar
• Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36:1981–1990. doi:10.1200/JCO.2018.78.085829718793
   PubMed Web of Science ®Google Scholar
• Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2737–2749. doi:10.1093/humrep/dew22427664208
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. Oncologist. 2015;20(11):1283–1289. doi:10.1634/theoncologist.2015-022326463871
   PubMed Web of Science ®Google Scholar
• Hornstein MD, Surrey ES, Weisberg GW, Casino LA; Lupron Add-Back Study Group. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol. 1998;91(1):16. doi:10.1016/S0029-7844(97)00620-09464714
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Pagani O, Partridge AH, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–217. doi:10.1016/j.breast.2017.07.01728822332
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines Adolescent and Young Adult (AYA) Oncology; 2018 Available from: https://www.nccn.org/professionals/physician_gls/pdf/aya.pdf. Accessed November 1, 2018.
   Google Scholar
• National Comprehensive Cancer Network. National Comprehensive Cancer Network Guidelines – Breast Cancer; 2018 Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed November 1, 2018.
   Google Scholar
• Muñoz M, Santaballa A, Segui´ MA, et al. SEOM Clinical Guideline of fertility preservation and reproduction in cancer patients. Clin Transl Oncol. 2016;18:1229–1236. doi:10.1007/s12094-016-1587-927896641
   PubMed Web of Science ®Google Scholar
• Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 2015;26:1533–1546. doi:10.1093/annonc/mdv22125939896
   PubMed Web of Science ®Google Scholar
• Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25–33. doi:10.1016/j.ejca.2016.10.03427940355
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Pagani O, Partridge AH, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87–99. doi:10.1016/j.breast.2015.12.01027017247
   PubMed Web of Science ®Google Scholar
• Vu JV, Llarena NC, Estevez SL, Moravek MB, Jeruss JS. Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients. J Surg Oncol. 2017;115:116–121. doi:10.1002/jso.2441827966219
   PubMed Web of Science ®Google Scholar
• Deshpande NA, Braun IM, Meyer FL. Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: a systematic review. Cancer. 2015;121:3938–3947. doi:10.1002/cncr.2963726264701
   PubMed Web of Science ®Google Scholar